Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
700

Summary

Conditions
Non -Small Cell Lung Cancer
Type
Interventional
Phase
Not Applicable
Design
Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Single (Participant)Masking Description: Results of 14-Gene prognostic assay will not be revealed to the patient. Low risk patients will be observed, intermediate and high risk patients will be randomized to observation or four cycles of a cisplatin-based doublet therapy.Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

Not Provided

Not Provided

Tracking Information

NCT #
NCT01817192
Collaborators
Encore Clinical
Investigators
Principal Investigator: David R Spigel, MD Sarah Cannon, The Cancer Institute of HCA Healthcare